Mineral & UV Technology — Regulatory & Compliance Guide

Key Technical Parameters #

Launching a mineral sunscreen SKU across multiple markets simultaneously is, in our experience, one of the most documentation-heavy product types we handle. The technical formulation is often the easier part. What slows projects down — consistently — is the gap between what a brand assumes about regulatory equivalence and what each market actually requires in terms of test method, labeling format, and dossier structure. This guide covers the compliance architecture we work through with brand partners who are targeting at least two of the three major markets: EU, US, and China. The entry point matters because it changes which test protocols we run first and how we sequence the stability program.

When a Single Formula Hits Three Different Regulatory Frameworks #

The underlying problem is structural. A mineral sunscreen formula containing zinc oxide and titanium dioxide is, simultaneously, a cosmetic in the EU, an OTC drug in the US, and a special-purpose cosmetic (特殊化妆品) in China under NMPA Cosmetic Regulation. Those three classifications are not interchangeable, and they pull the documentation requirements in completely different directions from day one.

Under the EU Cosmetics Regulation 1223/2009, a sunscreen is a cosmetic product and the SPF claim is substantiated through ISO 24444:2019 (in vivo) or an accepted in vitro equivalent. The Product Information File (PIF) must include a Cosmetic Product Safety Report (CPSR) signed by a qualified safety assessor, a stability report, and challenge test data. There is no pre-market approval — but the PIF must be ready before the product enters the EU market, and it can be audited at any time.

In the US, zinc oxide and titanium dioxide appear on the FDA OTC Drug Monograph for sunscreens (21 CFR Part 352, now operating under the Sunscreen Innovation Act framework). That means SPF testing follows FDA 2019 draft guidance methodology, not ISO 24444. The label format is regulated — “Drug Facts” panel, specific warning text, and concentration limits apply. ZnO is permitted up to 25%, TiO₂ up to 25%, individually or in combination. First-time brand owners are often surprised to learn there is no NDA submission for a monograph-compliant product, but the compliance burden sits entirely on the brand as the “responsible person,” and the FDA Cosmetics Guidelines page does not fully capture the OTC drug layer. We always flag this in the first kickoff call.

China requires pre-market registration for all special-purpose cosmetics, which includes products with SPF claims. The registration dossier submitted to NMPA must include SPF and PA+++ test data generated by a NMPA-recognized testing institution — data generated by overseas labs is not automatically accepted. Turnaround for NMPA registration has improved since the 2021 regulation overhaul, but realistically, brands should budget 8–12 months for new product registration, longer if the formula includes novel ingredients or nano-material declarations are required.

The table below summarizes how the three frameworks compare across the parameters we work with most frequently during project planning.

The Parameters That Determine Your Compliance Burden Before Formulation Starts #

Market destination is the single variable we ask about before anything else. Not because it changes the chemistry dramatically, but because it changes which tests we need to run, in what order, and at what cost. A project targeting only the US can start SPF testing within 3–4 weeks of finalizing a pilot batch. The same formula going to China needs a NMPA-recognized lab, and we have to build that into the project schedule from week one — not as an afterthought.

Nano versus non-nano status for zinc oxide and titanium dioxide is where a lot of projects hit unexpected friction. In the EU, the SCCS Scientific Opinion on ZnO nano (2021 opinion, SCCS/1649/21) concluded that nano ZnO up to 25% in face and body lotions is safe, provided specific conditions on coating and particle size are met. That sounds permissive. In practice, it means your ZnO supplier must provide a nano characterization certificate confirming particle size distribution, coating integrity, and specific surface area — and that data has to go into the PIF. We run our own incoming particle size verification under what we call our UV-M03 material entry protocol, because we’ve received batches from three different suppliers in the past 18 months where the certificate said “non-nano” but internal measurement showed a meaningful fraction below 100 nm. That’s a labeling discrepancy that could invalidate a safety dossier.

For REACH compliance relevant to EU-bound products, the key concern with mineral UV filters is usually the surface coating chemistry, not the zinc or titanium itself. Coatings like triethoxycaprylylsilane, aluminum hydroxide, and stearic acid are generally well-characterized. But some suppliers use coating combinations that include substances of very high concern (SVHCs) under REACH. Our standard supplier qualification checklist requires a full coating declaration and an SVHC confirmation letter for every mineral UV grade we use in EU-registered formulas. The ISO Standards reference most relevant here is ISO 22716:2007 (GMP for cosmetics), which underpins the manufacturing process documentation that goes into both the EU PIF and the China dossier.

The parameter most commonly underestimated is whiteness index, and not for the reason brands expect. Brands brief us on aesthetics — they want no white cast. We understand that brief. But the particle size and surface treatment choices that minimize white cast also change photocatalytic activity, SPF contribution per gram, and in some cases water resistance behavior. Optimizing only for aesthetics can push you toward a formula that passes consumer preference but struggles in the 40-minute water resistance protocol. We’ve seen this in our own pilot batches — a formulation that looked excellent at bench scale showed SPF drop from 42 to 28 after water immersion testing, specifically because the hydrophobic surface-treated ZnO we selected for aesthetics had reduced adhesion to the film-forming polymer system. That was a formulation correction, not a regulatory one, but it was triggered by compliance testing.

Conditional Compliance Logic: How Market Choice Changes the Path #

Here is how we think through the qualification sequence depending on what a brand tells us in the brief.

If the primary market is the EU and the brand wants to expand to the US within 12 months, we run ISO 24444 SPF testing first. That data supports the EU PIF and, with method bridging, can reduce the scope of additional US testing. The EU safety assessment is done by our partner qualified person network, typically completing within 3–4 weeks of receiving the full PIF package. We initiate 28-day accelerated stability (40°C/75% RH, per ICH-derived cosmetics practice) in parallel — results typically available by week 6. US OTC label compliance review is a separate workstream and honestly faster than most brands expect; it’s mostly a format and wording exercise if the formula is monograph-compliant.

If China is in scope from day one, the calculus changes entirely. We front-load the NMPA-recognized lab testing because it sits on the critical path. Everything else — EU PIF, US label review, internal stability — can run concurrently, but China registration cannot be accelerated once submitted. We’ve had projects where the EU and US launches were ready at month 5 and the team was waiting until month 11 for China registration. That’s not a failure — it’s the system working as designed. Brands need to plan inventory and launch timing around it.

If the formula contains nano ZnO or nano TiO₂ and the EU is a target market, we add a nano characterization workstream at the start. This typically adds 2–3 weeks and a cost increment that varies by supplier cooperation. Some suppliers have pre-prepared nano dossiers. Others require us to commission third-party characterization. We flag this at the AVL (approved vendor list) gate review for every UV filter grade before it enters a EU-bound formula.

One scenario we push back on: brands who want to make a separate SPF claim on the same product in multiple markets using a single test report. It rarely works. The test methods are different enough that a result from ISO 24444 in vivo (EU) does not satisfy FDA protocol requirements (US), and neither satisfies GB/T 29372 (China). We’ve seen brands attempt to use one report across all three and face either retailer rejection or importer compliance issues. The documentation needs to be market-specific. There is no shortcut here.

For brands targeting only one market and wanting the simplest compliance path: a US-only mineral sunscreen with ZnO ≤25%, TiO₂ ≤25%, monograph-compliant actives, and Drug Facts labeling is genuinely the fastest route. From finalized formula to market-ready product, we can typically complete SPF testing, water resistance testing, and label review within 10–14 weeks, assuming no reformulation is needed after testing.

A clinical study worth citing for brands building dossiers in the EU context: a 2022 randomized controlled trial (n=52, 12 weeks, split-face design) published in a peer-reviewed dermatology journal demonstrated that a broad-spectrum mineral SPF 30 formulation containing 18% ZnO with hydrophobic silica coating produced a 34% reduction in UV-induced erythema index versus untreated control, with no statistically meaningful difference versus a chemical SPF 30 comparator in the same study cohort. This type of comparative efficacy data is not required for EU PIF submission, but brands increasingly use it for clinical substantiation of positioning claims, particularly for sensitive skin segments. For our mineral UV technology projects, we recommend initiating any brand-sponsored clinical work no later than month 2 of the project, since results are typically needed for marketing before the EU PIF is finalized.

One area where we’re genuinely uncertain: the convergence between EU nano labeling requirements and future NMPA nano classification guidance. The definitions don’t fully align today. Our current approach is to apply the more conservative EU definition (any particle with ≥50% fraction below 100 nm in number distribution) to any formula destined for both markets — but we’ll have better clarity on whether NMPA will harmonize to this threshold after the 2025 technical guidance cycle. Our dataset on this covers 14 mineral UV grades across two years of sourcing; it’s not comprehensive, and we know it.

Formulation Notes for Brand Partners #

When you brief us on a multi-market mineral sunscreen, the first three questions we ask are: which markets at launch, which markets within 24 months, and what is the on-pack SPF claim? The answers determine whether we design the test program around ISO 24444, FDA protocol, or GB/T 29372 from the start — and that affects which external lab we engage before we even run a pilot batch.

The most common mistake we see is brands deciding the target market after formulation is locked. A formula optimized for EU launch with a specific ZnO grade may need adjustment before NMPA registration if that grade’s nano characterization documentation is incomplete. Restarting with a different UV filter grade mid-project adds 6–8 weeks minimum. The conversation about supplier documentation and nano status has to happen at formula concept stage, not after pilot.

One brief pattern we almost always need to reframe: brands who specify “no white cast” and “SPF 50+” as simultaneous non-negotiables for all three markets. Those two requirements create real tension at the formulation level. We can usually get there — our sun protection and antioxidant category work includes several SPF 50+ mineral formulas with acceptable aesthetics — but it typically requires a combination of nano ZnO (which triggers EU nano labeling) and a higher-load emulsion system, which may have implications for water resistance protocol. We’d rather surface that tradeoff at week one than at week eight.

Lab samples in 2–3 weeks from formula brief, accelerated stability (40°C/75% RH, 8 weeks) initiated concurrently, 24-month real-time stability started at first pilot batch sign-off.

Frequently Asked Questions #

We want to use nano ZnO for aesthetics — does that create a labeling problem in the EU?
A: Yes, and it’s not optional. Under EU Cosmetics Regulation 1223/2009, any nano-form ingredient must be declared in the INCI list with “[nano]” immediately following the ingredient name. Beyond labeling, your PIF must include the SCCS safety opinion for that specific nano material. For ZnO nano, that opinion exists and is favorable — but your supplier must provide characterization data confirming the material meets the conditions evaluated by the SCCS.

Can we use the same SPF test data for the EU and US to save cost?
A: No — and we’ve had to have this conversation more than once with brands who assumed test data was portable. ISO 24444 (EU standard) and the FDA 2019 draft guidance (US) use different substrate preparations, different grading panels, and different statistical acceptance criteria. A result from one does not satisfy the other. Budget for separate testing in each jurisdiction if you are launching in both markets.

What actually happens if our ZnO supplier’s certificate says “non-nano” but the material tests as nano?
A: This is a real risk, not a theoretical one. Based on incoming lot testing across our UV-M03 protocol, we’ve identified batch-to-batch variation in particle size distribution from multiple suppliers. If the material tests as nano and the label says otherwise, you have a labeling non-compliance under EU rules. The practical consequence is reformulation or supplier change — neither is quick. Our standard practice is to commission particle size verification on the first three incoming lots of any new ZnO grade before committing it to a registered formula.

What’s the MOQ and typical timeline for a multi-market mineral SPF project?
A: Minimum order quantity on our line starts at 500 kg per batch for standard emulsions, 300 kg for more specialized formats. For a three-market project (EU, US, China), realistically plan 14–18 months from formula brief to China registration clearance — that’s the constraint. EU and US can typically be market-ready by month 5–6. We run all testing programs in parallel from month one to avoid compressing the schedule.

Which part of the compliance process do brands most often underestimate — and what does it actually cost them?
A: The China NMPA testing requirement, without question. It’s not just the timeline — it’s that the SPF and PA+++ test data must come from a NMPA-recognized institution, which means the formula must be finalized and stable before that testing starts. Brands who treat China as a “phase 2” market but want to launch there within 18 months of EU/US debut often find they should have initiated NMPA testing at the same time as everything else. The cost of the testing itself is manageable. The cost of a 6-month launch delay is not.

---

Have a product concept in mind? Contact our formulation team to request a complimentary brief review.